# ARC-20 Trial

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/arc-20-trial
Canonical HTML page: https://getbiobrief.com/entity/arc-20-trial

## Recent coverage (1 stories)

### Casdatifan’s Phase 1 Data in 127 Kidney Cancer Patients Fuel HIF-2α Competition
2026-07-28 03:57:26 · Sentiment: Bullish · Impact: 7/10 · Sources: 2

Oral HIF-2α inhibitor casdatifan posted durable responses in the ARC-20 phase 1 trial of 127 heavily pretreated ccRCC patients, published in Nature. The data intensifies competition in the HIF-2α space, where Merck’s belzutifan is already approved, and sets the stage for pivotal trials.
Full story: https://getbiobrief.com/story/casdatifan-phase1-hif2a-competition

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.